1558037-97-0

Upstream product

• 1181816-12-5 6-oxo-2-aza-spiro[3.3]heptane-2-carboxylic acid tert-butyl ester 
• 1147557-97-8 6-hydroxy-2-aza-spiro[3.3]heptane-2-carboxylic acid tert-butyl ester 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1558038-16-6 C₂₇H₃₀N₄O₄ 
• 1558038-17-7 C₂₂H₂₂N₄O₂ 
• 1558038-33-7 C₂₉H₃₂N₂O₅S 
• 67460-86-0 3,5-dibromo-1H-pyrazole 
• 1448850-35-8 3-(4-phenoxyphenyl)-1-(2-azaspiro[3.3]heptan-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1448850-28-9 1-(6-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one 
• 1448850-34-7 tert-butyl 6-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-azaspiro[3.3]heptane-2-carboxylate 
• 1558038-64-4 C₂₄H₃₁N₅O₃ 
• 1558038-58-6 C₂₆H₂₈N₆O₃ 
• 1558038-40-6 C₂₇H₂₉N₅O₃ 
• 1558038-06-4 C₂₉H₃₃N₃O₅ 
• 1558037-36-7 C₂₂H₂₇N₅O₃ 
• 1558038-65-5 C₁₉H₂₅N₅O₂ 
• 1558037-32-3 C₂₄H₂₄N₆O₃ 

Relevant academic research and scientific papers

Pyrimidine compounds and their uses

The present invention proposes pyrimidine compounds and their uses, in particular, the present invention proposes a new compound that effectively inhibits ATX, which is a compound shown in the formula below, or a tautomer of the compound of the following

Stereoselective Diboration of Spirocyclobutenes: A Platform for the Synthesis of Spirocycles with Orthogonal Exit Vectors

The diastereo- and enantioselective diboration of spirocyclobutenes provides a platform for the rapid preparation of a wide variety of chiral spirocyclic building blocks. The chemoselective functionalization of the carbon-boron bond in the products, including a stereospecific sp3-sp2 Suzuki–Miyaura cross-coupling reaction, provides a powerful tool to control the directionality and the nature of the exit vectors in the spirocyclic framework.

PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS

The present application provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; method for manufacturing said compound, and its therapeutic uses. The present application further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR

Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.

Compound serving as IRARAK inhibitor as well as preparation method and application thereof (by machine translation)

The present invention relates to compounds useful for treating cancer and inflammatory diseases associated with interleukin -1 receptor-related kinases (IRARAK), in particular compounds shown as IRARARARAK-4 inhibitors, stereoisomers thereof, racemates, t

SUBSTITUTED THIENOPYRROLES AS PAD4 INHIBITORS

The present invention provides compounds of formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES

Provided is a compound of Formula (I): wherein the variable groups are defined herein.

Synthesis of Electron-Deficient Heteroaromatic 1,3-Substituted Cyclobutyls via Zinc Insertion/Negishi Coupling Sequence under Batch and Automated Flow Conditions

Synthesis of 1,3-substituted cyclobutyls enabled by zinc insertion into functionalized iodocyclobutyl derivatives followed by Negishi coupling with halo-heteroaromatics is reported. Two distinct sets of conditions were developed; the first involved a two-step batch protocol using activated Rieke zinc, and the second involved a multistep continuous flow process. Both methods showed complementarity and allowed for rapid access to these medicinally relevant motifs, the possibility of scaling up, and automation for library synthesis.

TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors with a Novel Monodentate Binding Interaction

Herein we describe the identification of 4-{[1,2,4]triazolo[1,5-a]pyridin-5-yl}benzonitrile-based inhibitors of the hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme. These inhibitors were shown to possess a novel binding mode by X-ray crystallography, in which the triazolo N1 atom coordinates in a hitherto unreported monodentate interaction with the active site Fe2+ ion, while the benzonitrile group accepts a hydrogen-bonding interaction from the side chain residue of Asn315. Further optimization led to potent PHD-1 inhibitors with good physicochemical and pharmacokinetic properties.